At a glance
ClinicalIndex Comparison RecordN/ACompleted· 761 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Long-Term Therapy Outcomes When Treating CKD-patients With Paricalcitol in German Clinical Practice (TOP Study)
In Brief
An observational study for Kidney Insufficiency and Secondary Hyperparathyroidism. Completed, enrolled 761 participants across 87 sites in 2 countries.
Detailed Summary
The purpose of this study is to obtain data on the safety and effectiveness of Zemplar® (paricalcitol) injection and paricalcitol capsules in real-life clinical practice. Participants, who have been treated with paricalcitol in-label in an everyday setting, have been included into this study. A period of 12 months has been chosen in order to also obtain experience on the maintenance dose and treatment optimization with paricalcitol injection and paricalcitol capsules in long-term use.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesAustria, Germany
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2008
First PostedMar 2010
Primary CompletionDec 2013
TodayJul 2026
First PostedMar 10, 2010
Enrollment StartMar 1, 2008
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 16.3 years ago